|
|
|
|
|
Last Trade
|
Last Trade:
$6.01
|
Change:
0.03 (0.50%)
|
Trade Time:
10:17 AM EST
|
Market Cap:
$206.15M
|
|
|
|
|
|
|
Description of Business
|
|
EyePoint Pharmaceuticals is a company committed to developing and
commercializing therapeutics to help improve the lives of patients with serious
eye disorders. The Company's pipeline leverages its proprietary Durasert®
technology (Durasert) for sustained intraocular drug delivery including delivery
of EYP-1901, an investigational sustained delivery intravitreal treatment
currently in Phase 2 clinical trials. The proven Durasert drug delivery platform
has been safely administered to thousands of patients' eyes across four U.S. FDA
approved products, including YUTIQ® for the treatment of posterior segment
uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is
headquartered in Watertown, Massachusetts.
Durasert allows for the development of a miniaturized solid cylinder of drug for
sustained "zero-order kinetics" release delivered through a single intravitreal
injection in the physician's office.
|
|
|
|